Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27149375 | 0.97 | IDO1 (0.50) | IDO1CES2DAOTAAR1RXRA | |
| Hydroquinone SCHEMBL28540141 | 0.87 | IDO1 (0.47) | IDO1RXRARXRBRXRGTACR1 | |
| SCHEMBL29738521 | 0.86 | IDO1 (0.41) | IDO1CES2DAOTAAR1MTOR | |
| SCHEMBL3591051 | 0.86 | IDO1 (0.41) | IDO1CES2DAOTAAR1MTOR | |
| SCHEMBL56666 | 0.86 | IDO1 (0.41) | IDO1DAOTAAR1RXRARXRB | |
| SCHEMBL29738541 | 0.86 | IDO1 (0.41) | IDO1DAOTAAR1RXRARXRB | |
| SCHEMBL18740304 | 0.84 | IDO1 (0.39) | IDO1CES2DAOTAAR1TSHR | |
| SCHEMBL1229494 | 0.84 | IDO1 (0.39) | IDO1TACR1TSHRCYP3A4CYP2D6 | |
| SCHEMBL799078 | 0.84 | IDO1 (0.39) | IDO1DAOTACR1 | |
| SCHEMBL6602321 | 0.81 | IDO1 (0.37) | IDO1CES2TAAR1TACR1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-11 | — | — | US | claimed |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2025-07-08 | — | — | US | claimed |
| CN-119751477-A | Lipid drop and hypochlorous acid sequence response type fluorescent probe and synthetic method and application thereof | 南宁师范大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119431278-A | Aromatic oxetanes and their use in encapsulation compositions | 华为技术有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-117700368-A | Synthesis method of pentanitrogen guanidine salt chiral phase transfer catalyst | 四川大学 | 2024-03-15 | — | — | CN | claimed |
| CN-117486852-A | Fluorine-containing rotaxane molecule and preparation method and application thereof | 中国科学院精密测量科学与技术创新研究院 | 2024-02-02 | — | — | CN | claimed |
| CN-113549062-B | Chiral quaternary ammonium salt phase transfer catalyst with high steric hindrance derived from cinchona alkaloid and synthesis method thereof | 南京工业大学 | 2022-08-09 | — | — | CN | claimed |
| US-20220073467-A1 | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-03-10 | — | — | US | claimed |
| EP-3902793-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) (AU) | 2021-11-03 | — | — | EP | claimed |
| WO-2020132716-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-07-02 | — | — | WO | claimed |
| CN-104181772-B | Two-photon activity photo-acid agent of the one kind using biphenyl as conjugated structure, preparation method and applications | 同济大学 | 2018-07-03 | — | — | CN | claimed |
| CN-104181772-A | Two-photon active photoacid generators taking biphenyl as conjugated structure and preparation method and application of two-photon active photoacid generators | UNIV TONGJI | 2014-12-03 | — | — | CN | claimed |
| US-7776952-B2 | Polymeric dispersant having an affinity with a supercritical fluid | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-08-17 | — | — | US | claimed |
| EP-1344772-B1 | ARYLBIS (PERFLUOROALKYLSULFONYL) METHANE, METAL SALT OF THE SAME, AND PROCESSES FOR PRODUCING THESE | JAPAN SCIENCE & TECH AGENCY (JP) | 2009-07-22 | — | — | EP | claimed |
| US-7339082-B2 | Arylbis (perfluoroalkylsulfonyl)methane and metallic salt thereof, and methods for producing the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-03-04 | — | — | US | claimed |
| US-20080039404-A1 | BIFUNCTIONAL ANALGESIC COMPOUNDS FOR OPIOID RECEPTOR AGONISTS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | UNIVERSITY OF ARIZONA (US) | 2008-02-14 | — | — | US | claimed |
| US-20060160946-A1 | Polymeric dispersant having an affinity with a supercritical fluid | SAMSUNG ELECTRONICS CO., LTD. | 2006-07-20 | — | — | US | claimed |
| US-20050070741-A1 | Arylbis (perfluoroalkylsulfonyl)methane and metallic salt thereof, and methods for producing the same | ISHIHARA KAZUAKI (JP) | 2005-03-31 | — | — | US | claimed |
| US-20040030192-A1 | Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof and methods for producing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1344772-A1 | ARYLBIS (PERFLUOROALKYLSULFONYL) METHANE, METAL SALT OF THE SAME, AND PROCESSES FOR PRODUCING THESE | Japan Science and Technology Corporation (JP) | 2003-09-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070741-A1 | Arylbis (perfluoroalkylsulfonyl)methane and metallic salt thereof, and methods for producing the same | TTI1, TTI2, TST | IDO1 3337/4885CES2 2419/4885DAO 1268/4885 |
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | SCN5A, MGMT, NISCH | IDO1 2316/4885CES2 1699/4885DAO 2189/4885 |
| US-20040030192-A1 | Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof and methods for producing the same | TTI1, TTI2, FLI1 | IDO1 3456/4885CES2 2321/4885DAO 1467/4885 |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | SCN5A, MGMT, NISCH | IDO1 2316/4885CES2 1699/4885DAO 2189/4885 |
| US-20220073467-A1 | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof | SCN5A, MGMT, NISCH | IDO1 2316/4885CES2 1699/4885DAO 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.